Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Johnson & Johnson

Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dulled the appetite on Wall Street for deal-making.

J&J's $13 billion bid for Shockwave turns to Wall Street for funding

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shockwave Medical (SWAV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Shockwave Medical (SWAV) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.03 per share a year ago.

Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release

In the latest trading session, Shockwave Medical (SWAV) closed at $328.99, marking a +0.04% move from the previous day.

Why the Market Dipped But Shockwave Medical (SWAV) Gained Today

Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.

Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors

Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Shockwave Medical (SWAV) Could Beat Earnings Estimates Again

Celsius Holdings

Coinbase

Robinhood

Interactive Brokers

We have narrowed our search to five high-flying Nasdaq Composite listed non-tech stocks with more upside left. These are: CELH, SWAV, COIN, HOOD, IBKR.

Top 5 Non-Tech Nasdaq Winners of Q1 With More Upside Left

Apartment Income REIT Corp

NEW YORK , April 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc. (NASDAQ: SWAV)'s  sale to Johnson & Johnson for $335.00 per share in cash. If you are a Shockwave shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, INRD

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Shockwave Medical, Inc. (Nasdaq: SWAV), relating to its proposed sale to Johnson & Johnson.

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Shockwave Medical, Inc. - SWAV

Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.

Shockwave Medical's (SWAV) Reducer Receives Positive Results

Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World' Study

On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.

Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?

News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.

Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?

NEW YORK, April 5, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Shockwave Medical, Inc. (NASDAQ: SWAV) and its board of directors concerning the proposed acquisition of the company by Johnson & Johnson (NYSE: JNJ). Stockholders will receive $335.00 for each share of Shockwave Medical stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.

Johnson & Johnson (JNJ) announced Friday it was buying Shockwave Medical (SWAV) for $13.1 billion in cash, pushing shares of the maker of cardiovascular catheters to near all-time highs.

J&J Acquires Shockwave Medical to Boost Its Cardiovascular Treatment Portfolio

Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave Medical. The companies announced on Friday that J&J will acquire Shockwave for $335 per share in cash funded through a combination of cash on hand and debt.

Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B

Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (JNJ) announced it would buy the company for $12.5 billion, boosting its portfolio of cardiovascular disease treatment devices.

Shockwave Medical Stock Rises After Johnson & Johnson Buyout

MILWAUKEE, April 5, 2024 /PRNewswire/-- Ademi LLP is investigating Shockwave (Nasdaq: SWAV) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join the https://www.ademilaw.com/case/shockwave-medical-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Shockwave Medical, Inc. has obtained a Fair Price in its transaction with Johnson & Johnson

The healthcare giant said the addition of the medical-device maker would expand its MedTech cardiovascular portfolio.

Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal

Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.

Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal

Johnson & Johnson (NYSE: JNJ ) is buying medical device company Shockwave Medical (NASDAQ: SWAV ) for $13.1 billion. Shockwave makes devices that perform Intravascular Lithotripsy.

News for Shockwave Medical Stock (SWAV)